anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present disclosure belongs to the field of health care products, disclosing a powder having effect on enhancing immunity, method for preparing the same and use thereof. The powder is made from synanthrin, Lycii Fructus, Poria, Lentinus edodes (Berk.) Sing, Mori Fructus, Chrysanthemi Flos, Codonopsis Radix, Flammulina velutipes, Hericium erinaceus and Tremella Fuciformis. The raw materials of the powder are all from natural Chinese herbal medicine without addition of excipient. It is clean and has natural components, in line with people's pursuit of natural and health foods. In addition, dosage required for the powder is small; it is easy to be taken and can be dissolved in water; it is soluble in cold water and can be absorbed quickly. The method for preparing the powder in the present disclosure is simple and suitable for large-scale production. Also, it is easy to be carried. The powder obtained has a good stability, long storage time, good taste. It melts in mouth and is soluble in cold water. Experiments show that the powder of the present disclosure can significantly enhance immunity, therefore can be used to prepare the health care foods having function on improving immunity.
FIELD: medicine, oncology. SUBSTANCE: invention proposes to use chitosan as a salt form with L-glutamic acid in combination with special phytospecies taken in the definite ratios and in different medicinal forms (ointments, infusions, extracts and dry extracts combined with powder-like chitosan salt form, tabletted, capsulated and pure forms). Treatment is carried out by specific schedule corresponding to stages of treatment of oncological diseases. Invention can be used for treatment of oncological patients at different stages and localization of tumors. EFFECT: enhanced effectiveness of treatment, prevention of adverse reactions, prolonged life of patient. 8 cl, 2 tbl, 11 ex
It is a single-center study, randomized, controlled, prospective cohort and interventional not blind. DAHF diagnosis will consider symptoms, physical examination, x ray and other image methods and BNP ou NTproBNP levels. Pulmonary infection diagnosis will "Infectious Disease Society of America / American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults" criteria, that include fever, cough, sputum, pleuritic pain, positive pulmonary image and physical examination. PCT and NTproBNP levels will be measured in miniVIDAS® (bioMérieux Clinical Diagnostics, France). Statistics includes descriptive analysis. Parametric data will be evaluated using T test and non parametric data with Mann-Whitney-Wilcoxon test. Multivariative analysis related to diagnosis, mortality and morbidity will be performed by Cox regression model. Sensibility and specificity will be calculated by ROC curve. Statistical significancy will be considered when p\<0.05.
Natural hybridisation is now recognised as pervasive in its occurrence across the Tree of Life. Resurgent interest in natural hybridisation fuelled by developments in genomics has led to an improved understanding of the genetic factors that promote or prevent species cross-mating. Despite this body of work overturning many widely held assumptions about the genetic barriers to hybridisation, it is still widely thought that ploidy differences between species will be an absolute barrier to hybridisation and introgression. Here, we revisit this assumption, reviewing findings from surveys of polyploidy and hybridisation in the wild. In a case study in the British flora, 203 hybrids representing 35% of hybrids with suitable data have formed via cross-ploidy matings, while a wider literature search revealed 59 studies (56 in plants and 3 in animals) in which cross-ploidy hybridisation has been confirmed with genetic data. These results show cross-ploidy hybridisation is readily overlooked, and potentially common in some groups. General findings from these studies include strong directionality of hybridisation, with introgression usually towards the higher ploidy parent, and cross-ploidy hybridisation being more likely to involve allopolyploids than autopolyploids. Evidence for adaptive introgression across a ploidy barrier and cases of cross-ploidy hybrid speciation shows the potential for important evolutionary outcomes.
The goal of the present study is to assess behavioral (primary) and neural effects of a multi-session cognitive training combined with transcranial direct current stimulation (tDCS). Many studies to date have found tDCS to be an efficient method to enhance various cognitive functions by modulating cortical excitability in young adults, but its behavioral impact and underlying mechanisms in aging still need to be elucidated. Healthy older adults will participate in a three-week cognitive training with concurrent online tDCS application. Cognitive performance (primary), as well as structural and functional imaging data will be examined before, during and after the intervention. In order to draw conclusions about the effect of tDCS in addition to cognitive training, a control group, receiving sham stimulation during training, will be assessed. Furthermore, to assess neural correlates of performance improvement, functional and structural parameters will be measured with MRI before and after training. Follow-up sessions to assess long-term effects are planned four weeks and six months after the post assessment. The results of the study will offer valuable insights into efficacy of combined tDCS and cognitive training, as compared to training alone, in older adults. Moreover, improved understanding of tDCS effects on cognitive training performance and underlying neural correlates may help to develop novel approaches for cognitive decline in healthy and pathological aging.
Embodiments are directed to an interactive text message based coaching program. A computer system generates customized messages for a first user containing information related to a health-related campaign program. The computer system generates the messages via a user interface in response to user-input provided by a second user. Messages are included in interaction components that include a user-specified link that logically connects the interaction component to another interaction component in a decision tree. The decision tree defines a sequence of messages to be sent to the first user. For example, a next message of the sequence can be based on a response from the first user to a previous message of the sequence.
A seven-year-old male neutered domestic shorthaired cat underwent surgical placement of a permanent epicardial pacemaker following diagnosis of intermittent second and third degree atrioventricular block, which was responsible for 'seizure-like' episodes. Although the pacemaker implant was successful, the cat started experiencing near-syncopal episodes approximately one year after surgery. Ambulatory Holter recording showed periods of loss of capture. Therefore, the pacemaker was interrogated using incremental energy output, which did not evoke any capture, even at the highest possible pulse voltage and duration. Thoracic radiographs showed that the pulse generator had rotated compared to the original radiographic assessment and the lead appeared entangled and shortened, resembling the findings described as 'twiddler syndrome' in humans and dogs, which is characterised by twisting of the lead caused by rotation of the pulse generator around its long axis and subsequent lead migration. To the best of the authors' knowledge, this is the first report of twiddler syndrome in a cat.
Valproic acid (VPA) is a long-chain fatty acid frequently used as an antiepileptic agent in pediatric and adult seizure patients. Other adverse effects that have been associated with VPA use include hepatic steatosis, altered mitochondrial function and decreased concentrations of serum proteins. The exact mechanism or mechanisms by which VPA induces these associated adverse drug effects are not fully understood though multiple theories have been postulated including impaired vesicle transport within the hepatocyte, inhibition of hepatic synthetic metabolic pathways and renal protein loss. Decreased serum albumin concentrations with concomitant VPA use have been identified in multiple studies. Albumin synthesis is sensitive to tryptophan concentrations (other amino acids are also able to stimulate albumin synthesis), oncotic pressure near the synthetic site, and energy supply while albumin release from the hepatocyte is sensitive to intrahepatocellular potassium concentrations. Based on available literature, VPA appears to inhibit an enzyme(s) either directly or indirectly involved with albumin synthesis or albumin gene expression. VPA is known to inhibit the urea cycle, including patients with ornithine-transcarbamylase (OTC) deficiency, possibly by inhibiting mitochondrial carbamoyl-phosphate synthase. Oratz et al discussed the potential correlation between the urea cycle and albumin synthesis identified after the administration of various amino acids increased both albumin and urea synthesis. Ornithine is an intermediate amino acid within the urea cycle and it is also a precursor to polyamines which have been shown to increase the degree of aggregation of polysomes, responsible for protein synthesis, bound to the endoplasmic reticulum. Thus, VPA may indirectly inhibit protein synthesis by interfering with the urea cycle leading to decreased ornithine concentrations and subsequently a decrease in polyamine concentrations and a decrease in the number of bound polysomes resulting in alterations in albumin synthesis and release. The purpose of this study is to investigate potential mechanisms of VPA-associated hypoalbuminemia in medically fragile pediatric and young adult epileptic patients of a long-term care facility.
Disclosed are an IL-5 binding molecule, and a preparation method and use thereof. The binding molecule includes the following complementarity determining regions: an amino acid sequence of CDR1 selected from any one of sequences as set forth in SEQ ID NOs. 43-49; an amino acid sequence of CDR2 selected from any one of sequences as set forth in SEQ ID NOs. 50-56; and an amino acid sequence of CDR3 selected from any one of sequences as set forth in SEQ ID NOs. 57-62. The binding molecule is capable of specifically binding to IL-5, and effectively blocking the cell proliferation induced by IL-5, and can be used for the prevention, diagnosis, and/or treatment of IL-5-associated diseases such as autoimmune disease.
The present invention provides a multi-drug-loading site and high drug-loading capacity ligand-drug conjugate. The ligand-drug conjugate has a structure of general formula (I). The ligand-drug conjugate has the characteristics of high loading capacity, high drug efficacy, low toxicity, and low risks. The ligand-drug conjugate can be used particularly to connect to a low toxicity chemical molecule, thereby extending a therapeutic window. Furthermore, the present invention provides an antibody-drug conjugate molecule. The antibody-drug conjugate molecule has the characteristics of multiple drug-loading ability and high drug-loading capacity, such that the antibody-drug conjugate can carry a large amount of a low toxicity chemical molecule and achieve a therapeutic effect without depending on antibody targeting or high toxicity chemicals.TM-{R2-PEG1-[R1-PEG2-(R3-A′-D)n]m}l  (I
FIELD: cosmetics. SUBSTANCE: invention relates to cosmetic composition used for irreversible deformation (curling or unbending) of keratin materials, preferably hair, and a method of their treatment by this composition. Composition is used for the first stage of irreversible deformation of keratin materials. It has at least one active agent for reduction of keratin disulfide bonds, one alkalizing agent and at least one cationic polymer. The agent is taken from the group involving ornithine, lysine and arginine. Cationic polymer has primary, secondary or tertiary amino-groups or quaternary ammonium groups in the main chain. Composition is made as lotion, viscous or liquid cream or gel. Reducing composition is applied on keratin material to be treated before, during or after their mechanical tightening on corresponding agents. Then keratin material is rinsed and oxidizing composition is applied before or after its separation from the tightening agent. After applying the reducing composition the latter is kept on keratin material for 5-60 min, preferably 5-30 min. Invention ensures to obtain good indices of irreversible deformation of keratin materials, in part, hair curling or unbending and decrease their damage. EFFECT: improved quality of composition. 15 cl, 1 tbl, 4 ex
The discovery discloses a shellfish antibacterial peptide P-AMP153 and application thereof. The amino acid sequence of the shellfish blood plasma antibacterial peptide P-AMP153 is shown in SEQ ID NO. 1. The invention separates a natural antibacterial peptide from the plasma of the crassostrea hongkongensis for the first time, and the antibacterial peptide has better function of eliminating bacteria by using the antibacterial peptide for bacteriostasis test verification and can be used for resisting the infection of gram-positive bacteria, gram-negative bacteria or fungi. The antibacterial peptide has a strong killing effect on vibrio alginolyticus, vibrio parahaemolyticus, escherichia coli, staphylococcus aureus and multidrug-resistant candida albicans, and has low cytotoxicity, strong antibacterial activity and high-efficiency broad-spectrum antibacterial effect. The P-AMP153 of the invention can be used as a substitute for antibiotics and has important values in the aspects of medical treatment and health, agricultural production, food industry and the like.
This group with receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
<P>PROBLEM TO BE SOLVED: To provide a medicine containing at least one double-stranded oligoribonucleotide (double-stranded RNA) designed to inhibit the expression of a target gene.  <P>SOLUTION: One strand of the double-stranded RNA is at least partially complementary to a targeted gene. The targeted gene can be selected from the following group: cancer genes, cytokine genes, Id protein genes, developmental genes, and prion genes. The target gene can be expressed in a pathogenic organism (especially Plasmodium). The targeted gene can preferably also be a part of viruses or viroids which are pathogenic to humans.  <P>COPYRIGHT: (C)2010,JPO&INPIT
BACKGROUND: The SCY1-like (SCYL) family has been reported to be closely related to cancer metastasis, but it has not been reported in gastric cancer (GC), and its specific mechanism is not clear.
METHODS: We utilized databases like Deepmap, TCGA, and GEO to identify SCYL1's role in GC. Clinical samples were analyzed for SCYL1 expression and its correlation with patient prognosis. In vitro and in vivo experiments were conducted to assess SCYL1's function in GC cell migration, invasion, and autophagy.
RESULTS: SCYL1 showed an increased expression in GC tissues, which correlated with a negative prognosis. In vitro experiments demonstrated that SCYL1 promotes GC cell migration and invasion and inhibits autophagy. GSEA indicated an inverse relationship between SCYL1 and autophagy, while a direct relationship was observed with the mTORC1 signaling pathway. Knockdown of SCYL1 enhanced autophagy, while activation of mTORC1 reversed this effect.
CONCLUSIONS: SCYL1 is a significant contributor to GC progression, promoting metastasis by activating the mTORC1 signaling pathway and inhibiting autophagy. These findings suggest SCYL1 as a potential therapeutic target for GC treatment.
Claudin 18.2 has emerged as a viable therapeutic target in gastric cancer (GC), but little is known about the heterogeneity of its expression in GC. This study investigated the heterogeneity of claudin 18.2 expression in 166 patients with metastatic GC whose surgical or paired primary-metastatic specimens were available. The prevalence of claudin 18.2 positivity (moderate-to-strong expression in ≥ 75% by the 43-14A clone) was 47.0%. Claudin 18.2-positive tumors exhibited more frequent peritoneal metastasis and a lower incidence of hepatic and distant lymph node involvement. Survival outcomes were comparable between patients with claudin 18.2-positive and -negative tumors. Intratumoral heterogeneity was noted in 38.5% of surgical specimens. Paired primary-metastatic site analysis revealed that 25.2% of patients had discordant results for claudin 18.2 positivity. Across different metastatic organ categories, peritoneal lesions showed the highest positivity rate (44.3%) and positive concordance rate (31.4%), whereas liver lesions had the lowest positivity rate (17.9%) and concordance rate (12.8%). In conclusion, claudin 18.2 expression exhibits intratumoral and intrapatient spatial heterogeneity in metastatic GC. Claudin 18.2 positivity is associated with more frequent peritoneal metastasis, and peritoneal lesions are more likely to have positively concordant claudin 18.2 results with the primary site than other metastatic sites.
Polymeric diffusion matrix for the application of anthraline (1,8,9-trihydroxyanthracene) or one of its derivs., to the skin, contains a cellulose ester and, as plasticiser, an alkyl ester of an aliphatic acid - the acid of which contains 5 - 18 carbon atoms and the alkyl gp. contains 3-18 C and is straight or branched chain. Used in treatment of skin ailments, esp. psoriasis. The anthraline does not oxidise, the compsn. does not cause staining to the skin or clothing, and it is non-irritant. The pref. cellulose esters are the acetobutyrates and acetopropionates, esp. those having a viscosity between 0.038 and 100 poises. The pref. plasticisers are isopropyl myristate and palmitate.
To maintain the blind in Protocol DIO-502, subjects will be re-randomized at Study Visit 1 to one of three doses of DIO-902: 150, 300 or 450 mg QHS. All subjects receiving DIO-902 placebo and 50% of subjects receiving DIO-902 will be re-randomized to one of three DIO-902 doses. The remaining 50% of subjects receiving DIO-902 will be assigned to their original DIO-902 dose. The re- randomization will be performed by a group independent of study conduct to ensure the treatment status of the subject while in Protocol DIO-502 remains blinded. In addition, subjects will continue on the same dose of metformin that they had been taking during the conduct of Protocol DIO-502. Subjects will continue on atorvastatin 10 mg for the first 4 weeks of this protocol. Thereafter, at Study Visits 3 and 4, the dose of atorvastatin may be increased up to a maximum of 40 mg daily in order to achieve LDL-cholesterol/non-HDL cholesterol goals specified within the protocol. In addition, after Study Visit 4 (Week 12) subjects with HbA1c levels of \> 7.5% (0.075 Hb Fract.) will undergo a one time titration of their oral hypoglycemic regimen as per the algorithm provided in the protocol.
BACKGROUND: A well-defined and clear procedure is a key factor supporting return-to-work and enhancing collaboration and understanding between employers and employees. The adaptation of the Tool for Support-Gradual Return to Work, TS-GRTW, addresses relevant cultural aspects valuable for wider adoption.
OBJECTIVE: develop a Swedish version, the GRTWswe, for implementation and integration into the Swedish labor market's RTW process. This involved translating, culturally adapting, and assessing the appropriateness and utility.
METHODS: In the initial step, a double back translation was performed to create an initial translated version. This version was then utilized in individual consultations, accompanied by an agreement questionnaire. For the subsequent step, group consultations were held to refine and customize the tool to suit the Swedish context. Ten occupational therapists completed the questionnaires, with mean agreement scores surpassing three on a four-point scale. Out of these, nine participated in group consultations.
RESULTS: The findings suggest the requirement for specific modifications to the GRTWswe. These adaptations are essential because of cultural differences in organizational structures and reference frameworks. Moreover, participants unanimously agreed to broaden the scope of target groups, encompassing employees without regard for diagnosis and expanding the range of professions that can utilize this tool. This step aims to enhance the tool's applicability and usefulness.
CONCLUSIONS: The study found strong alignment between questionnaire responses and group consultations outcomes, affirming the adapted tool's suitability for use in a Swedish context. The tool benefits employers and employees by enhancing communication, encouraging collaboration, and structuring processes, promising lasting improvements to work conditions.
Patients will, in addition to receiving standard follow-up every 6 months, also receive REBECCA-assisted follow-up at frequencies when the REBECCA-system indicate this. The patients will receive a REBECCA smartwatch that they will wear for 12 months. They will also have to install a REBECCA patient app on their mobile and a REBECCA plug-in on their computer for objective RWD collection related to their QoL and lifestyle over the next 12 months. The REBECCA system detects signs of deterioration in patients' QoL during the study period, the intervention will include changes in medication given, dietary advice, referral to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH) who will create a personalized training programme, e.g. 2-4 sessions per week.
A smart phone or tablet includes a first part having at least one laser diode configured to be pulsed, and a second part having at least one other laser diode, the laser diodes configured to generate near-infrared light, wherein at least some of the laser diodes comprise a distributed Bragg reflector, with some laser diode light directed to tissue including skin. An array of laser diodes generates near-infrared light and includes one or more distributed Bragg reflectors. An assembly in front of the array to forms light spots on the tissue. A first receiver includes detectors that receive light reflected from the tissue. An infrared camera generates data from light reflected from the tissue. The smart phone or tablet generates a two-dimensional or three-dimensional image or mapping using the infrared camera data, and includes a wireless receiver, a wireless transmitter, a display, a voice input module, and a speaker.
FIELD: veterinary science. SUBSTANCE: method involves administration the composition as powder that is fed with milk or colostrum to calves beginning from the 1-st day of life for 10 days, once per a day. Composition has the following components, mg: cobalt chloride, 5; copper sulfate, 20; zinc sulfate, 20; glucose, 500; abomasum mucosa dried extract, 250-300 and polfamix C, 1500-2000. Also, vitamin B 12  and ferroglucin-75 are administrated by intramuscular route in the dose 15.0 mg/kg on 1, 3 and 5 days of life in combination with indicated composition. Method ensures to diminish the disease period on an average by 3-5 days, to decrease calves morbidity with noninfectious diseases later on, to enhance safety of young stock. EFFECT: enhanced effectiveness of method. 2 tbl
Combination immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC). Induction Immunotherapy, followed by Maintenance Immunotherapy and potentially Retreatment. During retreatment, participants would receive the combination of Ipilimumab and Nivolumab or Nivolumab alone every three weeks for a maximum of one additional year.